Jump to:
Alyce Chen advises multinational companies in the life sciences, technology and other sectors on strategic transactions, with a focus on cross-border mergers, acquisitions, joint ventures and venture capital and growth equity investments. Alyce also regularly advises clients on corporate governance and compliance matters.
Experience
- Advised numerous life sciences and consumer goods companies in venture financing transactions from formation to exit and on corporate governance, intellectual property, and other ongoing commercial matters.
- Advised public companies in the life sciences and technology sectors on public company and securities compliance, including on Nasdaq and Hong Kong Stock Exchange compliance matters.
- Represented various venture capital firms investing in companies in the life sciences and consumer goods sectors in the U.S. and the Asia-Pacific region.
- Represented various multinational companies, including Eli Lilly, Pfizer, Johnson & Johnson and Fibrogen, in mergers, acquisitions, joint ventures and divestitures in the Asia-Pacific region.
- Represented Eli Lilly in its acquisition of Scorpion Therapeutics’ PI3Ka inhibitor program STX-478 for up to $2.5 billion.
- Represented HP, Inc. in its pending sale of Plamex and related assets (Mexico, China).
- Represented Qorvo, a provider of core technologies for radio frequency solutions, in the sale of its United Silicon Carbide subsidiary and the silicon carbide junction field-effect transistor (SiC JFET) technology business to onsemi.
- Represented Everest Medicines in the first cross-border mRNA vaccine equity and collaboration partnership in which an Asia-based biotechnology company received full technology transfer and manufacturing rights pertaining to proprietary mRNA technology developed by the licensor.